

Funds Management

# **Celeste Australian Small Companies Fund**

#### Performance Statistics (Total Returns net of fees)

	1 mth %	1 yr%	3 yrs % p.a.	5 yrs % p.a.	10 yrs % p.a.	15 yrs % p.a.
Celeste Aust. Small Co. Fund	+1.6	+67.1	+8.8	+13.4	+6.3	+7.4
Performance (relative to Index)	+0.8	+15.0	+0.5	+2.7	+2.2	+3.7
S&P/ASX Small Ords Acc Index	+0.8	+52.1	+8.3	+10.7	+4.1	+3.7
S&P/ASX Small Inds Acc Index	+1.7	+49.7	+9.2	+9.6	+8.7	+5.0
S&P/ASX Small Res Acc Index		+62.0	+5.0	+15.7	-6.7	+0.0

Past performance is not indicative of future returns. Total returns shown for the Celeste Australian Small Companies Fund has been calculated using exit prices after taking into account all of the Fund's ongoing fees and assuming reinvestment of distributions. No allowance has been made for entry fees or taxation.

#### **Portfolio Commentary**

The Fund rose 1.6%¹ in March, with its benchmark, the S&P/ASX Small Ordinaries Accumulation Index increasing by 0.8%. Since inception (May 1998) the Fund's return is 13.3% pa¹, net of all fees, against the Index's 6.1% pa.

Clover Corporation (CLV) rose 45.9% over March post reporting 1h21 results. While the 1h21 results were down on the previous period, the commentary surrounding the forward outlook was more positive. Inventory levels across the infant formula market appear to have normalised and forward demand for DHA (Omega-3) now looks likely to grow post Covid19 lockdowns and company closures coming back online. The infant formula licence changes in China on minimum DHA levels remains supportive of ongoing revenue growth at Clover over the next several years.

Hansen Technologies (HSN) rose 32.4% over the month. Existing growth momentum at HSN was boosted by a five year agreement signed with Telefónica Germany in early March, with associated revenues of approximately \$25m. HSN upgraded FY21 guidance on the back of this agreement, anticipating revenues in the range of \$306m - \$316m and an underlying EBITDA margin of 37% - 39%, an uplift of \$21m and 4% respectively on guidance provided at the 1h21 result. This is testament to Hansen's ability to deliver on the Sigma acquisition and compete in the global market, with further contract wins anticipated to follow.

**United Malt** (UMG) rose 11.5% over March driven by market sentiment around the Covid19 recovery. In both the UK and the US ongoing vaccination programs are re-opening both economies and this should see increased beer demand at pubs, clubs, restaurants and stadiums. Craft beer continues to grow as a percentage of the total beer market and the anticipated decimation of the industry post Covid19 has not occurred. Strong demand from the whiskey distilleries in Scotland should be supportive of volume growth from the greenfield CapEx program in the UK.

**Deterra Royalties** (DRR) fell 13.9% in March. DRR made no announcements of note, but its share price was buffeted by a weaker iron ore price. Iron ore prices peaked at \$175 US/t. early in March, before falling to \$167 US/t. at month-end. At current production levels of 56.2 m/t pa, a US \$ move of \$10 in the iron ore price, will move the profitability of DRR around \$10m pa. Whilst DRR sentiment will ebb and flow with iron ore pricing, we remain attracted to the expansion of royalty generating, BHP owned and operated, South Flank Mining Area C (MAC). We anticipate that DRR will rerate in the medium term, as the MAC production profile grows, its cash flow tenure is better understood, and franked dividend payments grow.

#### **Global Index Performance (Accumulation)**

	1 month %	1 year %	3 years % pa
Australia – S&P/ASX All Ordinaries	+1.8	+41.1	+10.1
USA-S&P 500	+4.2	+53.7	+14.6
USA – NASDAQ Composite	+0.4	+72.0	+23.3
Europe – FTSE (UK)	+3.6	+18.4	-1.6
Europe – DAX (Germany)	+8.9	+51.1	+7.5
Asia – Nikkei (Japan)	+0.7	+54.2	+10.8
Asia – Shanghai Composite (China)	-1.9	+25.1	+2.8

Monthly update: 31 March 2021

Source: IRESS

#### **Market Commentary**

The Small Ordinaries Index had a volatile March, rallying 7% from its intra-month low on March 5th to its high on March 16<sup>th</sup>, only to sell off towards month-end, with the Small Ordinaries Accumulation Index closing up only 0.8% for the month.

Domestically, economic data released in March continued to demonstrate the better than expected recovery in the Australian economy: the unemployment rate declined to 5.8% with 70k new jobs created for the month of February; retail sales for February were up 5.2% year on year; and house prices continued to surge, with national dwelling prices rising 2.8% in March, and 8.2% over the past six months.

Covid19 headlines remained quite mixed. Domestically, there was a minor outbreak of locally acquired cases, resulting in Brisbane being locked down for three days. Additionally the rate of vaccination remains exceedingly slow, well behind initial government projections. While the vaccine rollout continues globally, March saw snap lockdowns in Europe and also saw some European countries pause the rollout of the AstraZeneca vaccine citing safety concerns.

US Treasury yields, primarily the 10-year, remained the focus of investors, with the yield on the 10-year finishing the month at 1.74%, up 33.5bps from the end of February. The FOMC March statement noted that monetary policy was likely to remain accommodative, and that rates were likely to remain near zero to 2023. The FOMC maintained the target range for the Federal Funds rate at 0-0.25%, suggesting that this will remain the case till maximum employment is achieved and the inflation rate exceeds 2% for some time. Additionally, the Fed put through larger than expected upgrades to GDP and core PCE (personal consumption expenditure) forecasts, which were above 2% for 2021, 2022, and 2023.

Despite the increased cost of debt associated with the move in US Treasury yields, access to credit remains robust, with over US\$150b of new junk bond purchases in the US during the March quarter. We believe this remains a positive for broader equity markets, as it is likely to drive further capital management (share buy-backs) and fuel M&A activity. Given the volatility in markets, driven by the ascent of the yields, Celeste remains focussed on identifying stock-specific opportunities and remains disciplined with respect to valuation.

# **Portfolio Top 5 Holdings**

Stock	% of Fund
1 ARB CORPORATION	3.7
2 STEADFAST GROUP	3.7
3 CODAN	3.6
4 AUTOSPORTS GROUP	3.6
5 CITY CHIC COLLECTIVE	3.4

**Monthly update: 31 March 2021** 

# **Fund at a Glance**

#### **Fund Information**

Primary Investments	Shares in listed Australian smaller companies	
Investment objective	Exceed Small Ordinaries Accumulation Index over rolling 5 year periods	
Unit price (redemption) as at 31.03.2021	\$4.2836	
Unit price (application) as at 31.03.2021	\$4.3094	
Fund Size as at 31.03.2021	\$80m	
Minimum investment	\$25,000	
Minimum additional investment	\$1,000	
Minimum balance	\$15,000	
Redemption will generally be available in	7 days	
Distributions	30 June and 31 December	
Entry fee*	0%	
Exit fee*	0%	
Buy/Sell differential*	0.30%	
Management fee*	1.10% p.a	
Performance fee**	20% of return above benchmark	

<sup>\*</sup> These fees and charges apply for the duration of the Product Disclosure Statement (PDS) and are inclusive of the Goods and Services Tax.

### **Fund Returns**

## Celeste Australian Small Companies Fund (CASCF) versus CELESTE S&P/ASX Small Ordinaries Accumulation Index (SOAI) Net returns over periods ended 31 March 2021 80.0% CASCF SOAI 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 13.3% 8.8% 8.3% 10.0% 2.2% 2.1% 0.0% 3 months 1 year 3 years pa 5 years pa 10 years pa 15 years pa Inception pa

# Past performance is not indicative of future returns. Total returns shown for the Celeste Australian Small Companies Fund has been calculated using exit prices after taking into account all of the Fund's ongoing fees and assuming reinvestment of distributions. No allowance has been made for entry fees or taxation.

# **Distribution History**

Total distribution year ended	Cents Per Unit	
June 11	11.89	4.6
June 12	4.07	1.4
June 13	15.81	5.5
June 14	14.56	5.4
June 15	12.67	4.5
June 16	9.95	4.0
June 17	6.87	2.6
June 18	7.01	2.2
June 19	10.46	2.9
June 20	9.51	2.8

<sup>\*\*</sup> CPU / unit price at beginning of period

Celeste Funds Management Limited ABN 78 098 628 605 (AFSL 222 445) is authorised to provide financial product services to wholesale clients. This report is intended to provide only general securities information and is not to be construed as financial product advice, solicitation of an offer to buy or sell any financial product or a recommendation to buy, sell or hold a particular financial product. Accordingly, reliance should not be placed on this report as the basis for making an investment, financial or other decision. The information in this report does not take into account your investment objectives, financial situation or particular needs. Whilst every effort is taken to ensure the information in this report is accurate, its accuracy, reliability or completeness is not quaranteed.

This report has been issued by The Trust Company (RE Services) Limited ABN 45 003 278 831 (AFSL 235 150) (Perpetual) who is the Responsible Entity of and issuer of units in the Celeste Australian Small Companies Fund (Fund). Celeste Funds Management Limited is the investment manager of the Fund. Retail clients can invest in units in the Fund issued by Perpetual. Perpetual is authorised to deal with retail clients and a product disclosure statement (PDS) issued by Perpetual is available from Celeste Funds Management Limited (02) 9216 1800 or at <a href="https://www.celestefunds.com.au">www.celestefunds.com.au</a>. You should obtain and consider the PDS before deciding whether to acquire, or continue to hold, an interest in the Fund. Initial applications for units in the Fund can only be made pursuant to the application form attached to the PDS. Before making any decision to make or hold any investment in the Fund you should consider the PDS in full. You should consider your own investment objectives, financial situation and particular needs before acting upon any information provided and consider seeking advice from a financial advisor if

<sup>\*\*</sup> A fee charged on performance of the investments of the Fund above the nominated benchmark performance. The benchmark is the S&P/ASX Small Ordinaries Accumulation Index.

<sup>&</sup>lt;sup>1</sup> Total returns shown for the Celeste Australian Small Companies Fund has been calculated using exit prices after taking into account all of the Fund's ongoing fees and assuming reinvestment of distributions. No allowance has been made for entry fees or taxation. You should not base an investment decision simply on past performance. Past performance is not an indicator of future performance. Returns are not guaranteed and so the value of an investment may rise or fall.